Pfizer shares droop on Goldman downgrade; Mylan, Abbott settle fight over Depakote

> Already trading at their lowest levels in more than a decade, shares of Pfizer Inc. slipped in premarket trading Thursday after a Goldman Sachs analyst cut his rating on the drug maker's stock. Report

> Mylan and Abbott Laboratories have settled their patent fight over Depakote ER; the deal allows Mylan 180-day exclusivity on 500 mg tablets to be launched before January 1, 2009 and gives the generics maker a license for the 250 mg strength, too. Report

> Johnson & Johnson expects its $16.6 billion acquisition of Pfizer Consumer Health to break even or increase earnings modestly by 2009, a year earlier than previously expected. Report

> Novartis spent nearly $1.3 million lobbying the U.S. government in the first quarter on drug and health care issues. Report

> The University of Pittsburgh Medical Center might have the nation's strictest policies barring gifts and travel from the pharmaceutical industry, a recent study found. Report

> Researchers say they can cheaply and easily track how effective some cancer drugs are at cutting off a tumor's blood supply by using a technique called bioluminescence imaging. Report

And Finally ... Indonesia says it's going to keep bird-flu deaths quiet because publicizing them just makes the country look bad. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.